文献速递新发突发、热带与寄生虫病细菌感染、耐药与抗菌药物

东南亚多药耐药疟疾当前暴发的起源:一项回顾性遗传学研究

Origins of the current outbreak of multidrug-resistant malaria in southeast Asia: a retrospective genetic study.
PubMed 文献 · Lancet Infect Dis · 2018-02-02

该回顾性遗传学研究分析了东南亚11个地点1492份恶性疟原虫样本的基因组序列,其中柬埔寨西部2007至2013年间采集464份。研究发现青蒿素耐药有超过30个独立起源,KEL1谱系占双氢青蒿素-哌喹耐药寄生虫的91%(140/154);2008年KEL1与PLA1结合,至2013年KEL1/PLA1共同谱系在柬埔寨西部频率达63%(24/38)并扩散至柬埔寨北部。

要点

  • 青蒿素耐药在东南亚有超过30个独立起源,KEL1谱系占双氢青蒿素-哌喹耐药寄生虫的91%(140/154)。
  • 2008年KEL1与哌喹耐药主要谱系PLA1结合,形成KEL1/PLA1共同谱系。
  • 至2013年KEL1/PLA1共同谱系在柬埔寨西部频率达63%(24/38),并扩散至柬埔寨北部。

核心结论

  • KEL1/PLA1共同谱系在双氢青蒿素-哌喹成为柬埔寨西部一线抗疟药的同年出现,此后迅速传播并取代其他青蒿素耐药寄生虫谱系。
  • 这些发现对管理东南亚当前多药耐药疟疾暴发相关的全球健康风险具有重要意义。

研究设计与样本

  • 回顾性遗传学研究,分析东南亚11个地点1492份恶性疟原虫样本的基因组序列数据,其中柬埔寨西部2007至2013年间采集464份。
  • 通过kelch13青蒿素耐药位点和plasmepsin 2-3哌喹耐药位点的单倍型分析,鉴定耐药的不同流行病学起源。

主要发现

  • 鉴定出超过30个独立的青蒿素耐药起源,其中KEL1谱系占双氢青蒿素-哌喹耐药寄生虫的91%(140/154)。
  • 2008年KEL1与PLA1(与哌喹耐药相关的主要谱系)结合。
  • 至2013年,KEL1/PLA1共同谱系在柬埔寨西部频率达63%(24/38),并已扩散至柬埔寨北部。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antimalarial resistance is rapidly spreading across parts of southeast Asia where dihydroartemisinin-piperaquine is used as first-line treatment for Plasmodium falciparum malaria. The first published reports about resistance to antimalarial drugs came from western Cambodia in 2013. Here, we analyse genetic changes in the P falciparum population of western Cambodia in the 6 years before those reports. METHODS: We analysed genome sequence data on 1492 P falciparum samples from 11 locations across southeast Asia, including 464 samples collected in western Cambodia between 2007 and 2013. Different epidemiological origins of resistance were identified by haplotypic analysis of the kelch13 artemisinin resistance locus and the plasmepsin 2-3 piperaquine resistance locus. FINDINGS: We identified more than 30 independent origins of artemisinin resistance, of which the KEL1 lineage accounted for 140 (91%) of 154 parasites resistant to dihydroartemisinin-piperaquine. In 2008, KEL1 combined with PLA1, the major lineage associated with piperaquine resistance. By 2013, the KEL1/PLA1 co-lineage had reached a frequency of 63% (24/38) in western Cambodia and had spread to northern Cambodia. INTERPRETATION: The KEL1/PLA1 co-lineage emerged in the same year that dihydroartemisinin-piperaquine became the first-line antimalarial drug in western Cambodia and spread rapidly thereafter, displacing other artemisinin-resistant parasite lineages. These findings have important implications for management of the global health risk associated with the current outbreak of multidrug-resistant malaria in southeast Asia. FUNDING: Wellcome Trust, Bill & Melinda Gates Foundation, Medical Research Council, UK Department for International Development, and the Intramural Research Program of the National Institute of Allergy and Infectious Diseases.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Amato R, Pearson RD, Almagro-Garcia J, et al. Origins of the current outbreak of multidrug-resistant malaria in southeast Asia: a retrospective genetic study. Lancet Infect Dis. 2018. PMID: 29398391. doi:10.1016/S1473-3099(18)30068-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。